+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generalized Anxiety Disorder Market - Global Forecast 2026-2032- Product Image
Generalized Anxiety Disorder Market - Global Forecast 2026-2032- Product Image
New

Generalized Anxiety Disorder Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6016467
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Generalized Anxiety Disorder Market is undergoing a period of dynamic transformation as clinical, commercial, and technological advancements converge to redefine care delivery and stakeholder strategy. Senior leaders face shifting expectations as diverse patient cohorts, evolving therapies, and operational considerations reshape how anxiety care is delivered, measured, and commercialized.

Market Snapshot: Growth, Drivers, and Forecast

The Generalized Anxiety Disorder Market grew from USD 2.36 billion in 2025 to USD 2.50 billion in 2026 and is projected to reach USD 3.48 billion by 2032, reflecting a CAGR of 5.69%. Growth is fueled by digital health adoption, emerging treatment modalities, and expanded care models that prioritize both scalability and individualized outcomes. Evolving regulatory frameworks, strong payer interest in value-based models, and investments in scalable technology platforms further support sector expansion.

Scope & Segmentation: Trends and Opportunity Landscape

  • Treatment Modalities: Digital therapeutics, over-the-counter supplements, prescription pharmaceuticals, and therapeutic services comprise the primary intervention types. Digital therapeutics now span mobile apps, online platforms, and immersive virtual reality.
  • Distribution Pathways: Hospital pharmacies, retail pharmacies, e-commerce, and telepharmacy are extending access; online presence is reshaping adherence and privacy dynamics for stakeholders.
  • Demographic Cohorts: Patient strata include children, adolescents, adults, and elderly populations, with gender differences shaping engagement, comorbidity, and modality preferences.
  • Symptom Severity: Approaches range from stepped-care for mild symptoms to integrated, multidisciplinary management for complex or severe cases.
  • Technologies: Telehealth, remote monitoring, asynchronous care models, and digital phenotyping tools are widening the toolkit for tailored interventions and data-driven decision-making.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific feature distinct regulatory environments, levels of digital adoption, and cultural attitudes impacting access, commercialization, and value assessment.

Key Takeaways for Senior Decision-Makers

  • Stakeholders are moving toward measurement-based care and outcome tracking, aligning reimbursement and care coordination with patient-reported progress and engagement data.
  • Technological advances are supporting scalable care models, such as asynchronous digital tools and enhanced data interoperability, that reduce access barriers and optimize clinical resource use.
  • Workforce limitations have driven wider adoption of guided self-help platforms and task-shifting strategies, expanding capacity and improving intervention reach.
  • Therapeutic offerings are increasingly segmented by patient age, gender, and symptom profile, facilitating improved treatment matching and targeted product development.
  • Provider, payer, and industry partnerships are enabling innovative reimbursement, co-development agreements, and jointly piloted integrated care models to accelerate adoption and demonstrate value in real-world settings.
  • Regional regulatory frameworks, digital infrastructure, and local health priorities necessitate adaptive commercialization strategies to address variable access and acceptance.

Tariff Impact on Supply Chains and Procurement

Recent changes in U.S. tariff policy have created notable challenges for companies sourcing pharmaceutical ingredients and device components internationally. Manufacturers face heightened landed costs, customs volatility, and supply chain delays, leading to increased operational risk and shifts in procurement strategy. Healthcare providers and payers are responding with diversified supply sources, collaborative procurement models, and focus on flexible therapeutics to ensure continuity of care regardless of upstream disruptions.

Methodology & Data Sources

This report utilizes a mixed-method research approach, integrating qualitative expert interviews, secondary literature review, and scenario-based policy analysis. Insights reflect triangulated evidence from clinicians, technology developers, payers, and operational specialists, ensuring rigorous and actionable findings for industry leaders.

Why This Report Matters

  • Senior leaders can leverage actionable intelligence for investment, segmentation, and regional expansion planning built on transparent, evidence-based analysis.
  • Operational and clinical teams benefit from a clear understanding of supply risk, technological integration, and outcome measurement trends shaping the future of anxiety care delivery.

Conclusion

Integrated, evidence-aligned strategies will underpin future growth within the Generalized Anxiety Disorder Market. Careful attention to regional context, stakeholder collaboration, and resilient operational planning positions organizations to meet evolving patient and health system needs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Generalized Anxiety Disorder Market, by Treatment Type
8.1. OTC Supplements
8.2. Prescription Drugs
8.2.1. Benzodiazepines
8.2.2. Buspirone
8.2.3. SNRIs
8.2.4. SSRIs
8.3. Therapy Services
8.3.1. Cognitive Behavioral Therapy
8.3.2. Group Therapy
8.3.3. Psychodynamic Therapy
8.3.4. Supportive Counseling
9. Generalized Anxiety Disorder Market, by Gender
9.1. Female
9.2. Male
10. Generalized Anxiety Disorder Market, by Symptom Severity
10.1. Mild
10.2. Moderate
10.3. Severe
11. Generalized Anxiety Disorder Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.2.1. E-Commerce Portals
11.2.2. Telepharmacy Services
11.3. Retail Pharmacies
12. Generalized Anxiety Disorder Market, by Patient Age Group
12.1. Adolescents
12.2. Adults
12.3. Children
12.4. Elderly
13. Generalized Anxiety Disorder Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Generalized Anxiety Disorder Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Generalized Anxiety Disorder Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Generalized Anxiety Disorder Market
17. China Generalized Anxiety Disorder Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Allergan plc
18.6. AstraZeneca plc
18.7. Boehringer Ingelheim International GmbH
18.8. Bristol-Myers Squibb Company
18.9. Eli Lilly and Company
18.10. GlaxoSmithKline plc
18.11. H. Lundbeck A/S
18.12. Jazz Pharmaceuticals plc
18.13. Johnson & Johnson Services, Inc.
18.14. Merck & Co., Inc.
18.15. Mylan N.V.
18.16. Novartis AG
18.17. Otsuka Pharmaceutical Co., Ltd.
18.18. Pfizer Inc.
18.19. Roche Holding AG
18.20. Sanofi S.A.
18.21. Sumitomo Pharma Co., Ltd.
18.22. Sun Pharmaceutical Industries Ltd.
18.23. Takeda Pharmaceutical Company Limited
18.24. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY OTC SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY OTC SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY OTC SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY BUSPIRONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY BUSPIRONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY BUSPIRONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SNRIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SNRIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SSRIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SSRIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GROUP THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GROUP THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GROUP THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PSYCHODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PSYCHODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PSYCHODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SUPPORTIVE COUNSELING, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SUPPORTIVE COUNSELING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SUPPORTIVE COUNSELING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY E-COMMERCE PORTALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY E-COMMERCE PORTALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY E-COMMERCE PORTALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TELEPHARMACY SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TELEPHARMACY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TELEPHARMACY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 122. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 125. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 126. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 127. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 128. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 130. EUROPE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 140. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 142. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 143. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 144. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 145. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 146. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 148. AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 161. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 162. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 163. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 164. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 165. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 167. ASEAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 168. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 170. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 171. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 172. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 173. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 174. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 175. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 176. GCC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 186. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 189. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 190. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 191. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 192. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 194. BRICS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 195. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 197. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 198. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 199. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 200. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 201. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 203. G7 GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 204. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 206. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 207. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 208. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 209. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 210. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 212. NATO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 213. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 223. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
TABLE 226. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPY SERVICES, 2018-2032 (USD MILLION)
TABLE 227. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 228. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SYMPTOM SEVERITY, 2018-2032 (USD MILLION)
TABLE 229. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 231. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Generalized Anxiety Disorder market report include:
  • Allergan plc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.48 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Generalized Anxiety Disorder Market Report and Forecast 2025-2034 - Product Image

Generalized Anxiety Disorder Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Generalized Anxiety Disorder - Pipeline Insight, 2025 - Product Image

Generalized Anxiety Disorder - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
General Anxiety Disorder (GAD) - Pipeline Insight, 2025 - Product Image

General Anxiety Disorder (GAD) - Pipeline Insight, 2025

  • Clinical Trials
  • 40 Pages
  • Global
From
Generalized Anxiety Disorder Market Report 2025 - Product Image

Generalized Anxiety Disorder Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Anxiety Disorder Treatment - Global Strategic Business Report - Product Image

Anxiety Disorder Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From

About the Market

Generalized Anxiety Disorder (GAD) is a prevalent mental health condition characterized by chronic and excessive worry about multiple events or activities, often disproportionate to the actual likelihood or impact of the perceived threats. The GAD market encompasses a range of treatments and services aimed at managing symptoms and improving quality of life for individuals diagnosed with this disorder. Therapeutic approaches include pharmacotherapy, with medications such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) being commonly prescribed. Psychotherapy, particularly cognitive-behavioral therapy (CBT), is also a core component of treatment, offering strategies to modify anxious thought patterns and reduce avoidance behaviors. Additionally, the market includes supportive services such as self-help groups and online resources aimed at educating patients and carers about the disorder. Several pharmaceutical and healthcare companies are active in the GAD market, providing medications, therapies, and services to patients. Some notable players in this market include Pfizer, with products like sertraline (Zoloft), and Eli Lilly, which manufactures duloxetine (Cymbalta). Moreover, GlaxoSmithKline's paroxetine (Paxil) is another therapeutic option for GAD. On the psychotherapeutic front, companies like Talkspace and BetterHelp offer online counseling services, expanding access to mental health care. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.